Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 82 results for colitis

  1. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

  2. ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)

    NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .

  3. Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal (IPG642)

    Evidence-based recommendations on Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal in adults. This involves using the ileum to create a pouch on the inside of the abdominal wall to collect waste.

  4. What is the effectiveness of oral tacrolimus and systemic (intramuscular/subcutaneous/oral) methotrexate in the induction of remission in mild-to-moderate ulcerative colitis unresponsive to aminosalicylates?

    methotrexate in the induction of remission in mild-to-moderate ulcerative colitis unresponsive to aminosalicylates? Any explanatory...

  5. What is the clinical and cost effectiveness of prednisolone, budesonide, and beclometasone in addition to aminosalicylates compared with each other and with aminosalicylate monotherapy for the induction of remission for people with mild-to-moderate ulcerative colitis?

    the induction of remission for people with mild-to-moderate ulcerative colitis? Any explanatory notes(if applicable) To find out why the...

  6. Taking a proportionate approach to technology appraisals

    Find out more about NICE's new proportionate approach to technology appraisals

  7. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

  8. What is the clinical and cost effectiveness of prednisolone compared with aminosalicylates for the induction of remission for people with moderate ulcerative colitis?

    ulcerative colitis? Any explanatory notes(if applicable) Source guidance details Comes from guidance Ulcerative colitis:...

  9. What is the clinical and cost effectiveness of prednisolone plus an aminosalicylate compared with beclometasone plus an aminosalicylate for induction of remission for people with moderate ulcerative colitis?

    ulcerative colitis? Any explanatory notes(if applicable) Source guidance details Comes from guidance Ulcerative colitis:...

  10. What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids?

    placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids? Any...

  11. Spondyloarthritis (QS170)

    This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

  12. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

  13. Adenoma types and risk of colorectal cancer:- Does the risk of colorectal cancer depend on the type of adenoma?

    cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date issued

  14. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.